89.50
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$87.68
Offen:
$88
24-Stunden-Volumen:
15.24M
Relative Volume:
1.19
Marktkapitalisierung:
$251.88B
Einnahmen:
$64.17B
Nettoeinkommen (Verlust:
$17.12B
KGV:
13.30
EPS:
6.7297
Netto-Cashflow:
$14.84B
1W Leistung:
+7.82%
1M Leistung:
-7.00%
6M Leistung:
-22.86%
1J Leistung:
-30.14%
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Vergleichen Sie MRK mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
MRK
Merck Co Inc
|
89.50 | 251.88B | 64.17B | 17.12B | 14.84B | 6.7297 |
![]()
LLY
Lilly Eli Co
|
873.68 | 830.35B | 45.04B | 10.59B | 414.30M | 11.71 |
![]()
NVO
Novo Nordisk Adr
|
88.08 | 390.99B | 42.09B | 14.65B | 10.11B | 3.2833 |
![]()
ABBV
Abbvie Inc
|
202.08 | 356.74B | 56.33B | 4.28B | 17.83B | 2.40 |
![]()
JNJ
Johnson Johnson
|
162.30 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
2025-01-08 | Herabstufung | Truist | Buy → Hold |
2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2024-12-10 | Fortgesetzt | BofA Securities | Buy |
2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
2023-10-20 | Hochstufung | UBS | Neutral → Buy |
2023-07-14 | Eingeleitet | HSBC Securities | Hold |
2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2023-03-06 | Eingeleitet | Jefferies | Buy |
2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
2021-12-17 | Eingeleitet | Goldman | Buy |
2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
2021-12-13 | Herabstufung | UBS | Buy → Neutral |
2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
2021-11-01 | Hochstufung | Argus | Hold → Buy |
2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2021-07-27 | Fortgesetzt | Truist | Buy |
2021-05-20 | Herabstufung | Argus | Buy → Hold |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
2020-11-10 | Fortgesetzt | Bernstein | Outperform |
2020-09-29 | Eingeleitet | Berenberg | Hold |
2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2020-02-27 | Eingeleitet | Barclays | Overweight |
2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
2019-07-03 | Eingeleitet | Mizuho | Buy |
2019-05-28 | Eingeleitet | Goldman | Neutral |
2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
2018-10-16 | Bestätigt | Citigroup | Buy |
2018-10-09 | Fortgesetzt | Guggenheim | Buy |
2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Why Merck (MRK) is a Great Dividend Stock Right Now - Yahoo Finance
Hyperlipidemia Drugs Market Size to Promote USD 31.49 Bn by 2034 - GlobeNewswire Inc.
INVESTOR ALERT: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Financial Times
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRK - Markets Insider
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Merck & Co., - GlobeNewswire
Merck president Johannes Oosthuizen sells $714,744 in stock - Investing.com
Shareholders that lost money on Merck & Co., Inc.(MRK) - GlobeNewswire
Redburn Atlantic Adjusts Price Target on Merck to $115 From $148, Maintains Buy Rating - Marketscreener.com
Merck & Co., Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before April 14, 2025 to Discuss Your RightsMRK - PR Newswire
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors - GlobeNewswire
LA Gardasil Trial Against Merck Bagged After 3 Weeks - Law360
MERCK & CO., INC. (NYSE: MRK) INVESTOR ALERT: Investors With Large Losses in Merck & Co., Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights - TradingView
Merck vaccine trial delayed as RFK Jr. link creates jury concern - Los Angeles Times
August 15th Options Now Available For Merck (MRK) - Nasdaq
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
Merck & Co. digs into 'junk DNA' for cancer clues in new Epitopea deal - FirstWord Pharma
Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production - PharmaVoice
Merck & Co. Stockholder Notice: Shareholder Rights Law Firm - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
Merck & Co., Inc. (MRK): Among the Cheap High Dividend Stocks to Invest In Now - Insider Monkey
Merck Agrees to Halt Gardasil Trial Until September -February 18, 2025 at 03:19 pm EST - Marketscreener.com
MRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - Marketscreener.com
Merck cancer drug Welireg approved in EU (MRK:NYSE) - Seeking Alpha
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – MRK - GlobeNewswire
Investors in Merck & Co., Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – - EIN News
Looking Into Merck & Co's Recent Short Interest - Benzinga
Gilead upped on HIV franchise; Merck downgraded on Keytruda LoE at Deutsche Bank - Seeking Alpha
Is Merck & Co., Inc. (MRK) the Best Very Cheap Stock To Buy Right Now? - Yahoo Finance
Europe Approves Merck's Cancer Drug For Two Indications - Yahoo Finance
Exclusive-Merck vaccine case linked to HHS Secretary Kennedy delayed, company says - Marketscreener.com
Merck Gets Conditional Approval in EU for Drug Treating Von Hippel-Lindau Disease - Marketscreener.com
DBS Bank Adjusts Price Target on Merck to $100 From $168 -February 18, 2025 at 10:23 am EST - Marketscreener.com
MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Merck: EU approves WELIREG treatment -February 18, 2025 at 10:16 am EST - Marketscreener.com
Beyond The Numbers: 13 Analysts Discuss Merck & Co Stock - Benzinga
Deutsche Bank Downgrades Merck to Hold From Buy, Cuts Price Target to $105 From $128 - Marketscreener.com
Merck & Co., Inc. (MRK): Among the Best Drug Stocks to Buy Now - Insider Monkey
Merck's SWOT analysis: stock faces challenges amid gardasil setback, pipeline potential - Investing.com
Merck Downgrade Sparks Urgent Investor Decisions: Time to Shift Focus? - MotoPaddock
MRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire
Jim Cramer Comments on Merck & Co., Inc. (MRK) and Its China Woes - MSN
Is Merck & Co., Inc. (MRK) the Most Oversold S&P 500 Stock in 2024? - Yahoo Finance
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Insider trades: Merck, McDonald's among notable names this week (NYSE:MRK) - Seeking Alpha
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Markets Insider
MRK INVESTOR NOTICE: Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire
Accretive Wealth Partners LLC Makes New $531,000 Investment in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Empire Life Investments Inc. - MarketBeat
Rhumbline Advisers Cuts Stock Holdings in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Valeo Financial Advisors LLC Has $8.83 Million Stake in Merck & Co., Inc. (NYSE:MRK) - MarketBeat
Merck & Co., Inc. (NYSE:MRK) Shares Sold by Red Cedar Investment Management LLC - MarketBeat
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):